PHI was recognized by the FDA in June 2012 as an efficient clinical test for the early detection of prostate cancer in men >50 years of age, with PSA levels between 4.0 and 10.0 ng/mL and without any clinical modification on the digital rectal examination (DRE) of the prostate [68]. Here, KLK3 is linked to prostate cancer.